



### **SNCA Blocking Peptide (C-term)**

Synthetic peptide Catalog # BP21113a

#### **Specification**

SNCA Blocking Peptide (C-term) - Product Information

Primary Accession <u>P37840</u>

SNCA Blocking Peptide (C-term) - Additional Information

**Gene ID** 6622

#### **Other Names**

Alpha-synuclein, Non-A beta component of AD amyloid, Non-A4 component of amyloid precursor, NACP, SNCA, NACP, PARK1

#### Target/Specificity

The synthetic peptide sequence is selected from aa 92-105 of HUMAN SNCA

#### **Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

#### Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

#### **Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

SNCA Blocking Peptide (C-term) - Protein Information

Name SNCA

Synonyms NACP, PARK1

#### **Function**

Neuronal protein that plays several roles in synaptic activity such as regulation of synaptic vesicle trafficking and subsequent

# SNCA Blocking Peptide (C-term) - Background

May be involved in the regulation of dopamine release and transport. Induces fibrillization of microtubule-associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase-3 activation.

## SNCA Blocking Peptide (C-term) - References

Ueda K.,et al.Proc. Natl. Acad. Sci. U.S.A. 90:11282-11286(1993).
Campion D.,et al.Genomics 26:254-257(1995).
Ueda K.,et al.Biochem. Biophys. Res. Commun. 205:1366-1372(1994).
Xia Y.,et al.Submitted (JAN-1996) to the EMBL/GenBank/DDBJ databases.
Touchman J.W.,et al.Genome Res. 11:78-86(2001).



neurotransmitter release. Participates as a monomer in synaptic vesicle exocytosis by enhancing vesicle priming, fusion and dilation of exocytotic fusion pores (PubMed:<a href="http://www.uniprot.org/c itations/28288128" target=" blank">28288128</a>, PubMed:<a href="http://www.uniprot.org/ci tations/30404828" target=" blank">30404828</a>). Mechanistically, acts by increasing local Ca(2+) release from microdomains which is essential for the enhancement of ATP-induced exocvtosis (PubMed:<a href=" http://www.uniprot.org/citations/30404828" target=" blank">30404828</a>). Acts also as a molecular chaperone in its multimeric membrane-bound state, assisting in the folding of synaptic fusion components called SNAREs (Soluble NSF Attachment Protein REceptors) at presynaptic plasma membrane in conjunction with cysteine string protein-alpha/DNAJC5 (PubMed:<a hr ef="http://www.uniprot.org/citations/20798 282" target=" blank">20798282</a>). This chaperone activity is important to sustain normal SNARE-complex assembly during aging (PubMed:<a href="http://www. uniprot.org/citations/20798282" target=" blank">20798282</a>). Plays also a role in the regulation of the dopamine neurotransmission by associating with the dopamine transporter (DAT1) and thereby modulating its activity (PubMed:<a href="http://www.uniprot.org/citations/2644 2590" target=" blank">26442590</a>).

#### **Cellular Location**

Cytoplasm. Membrane. Nucleus. Cell junction, synapse. Secreted Note=Membrane-bound in dopaminergic neurons

#### **Tissue Location**

Highly expressed in presynaptic terminals in the central nervous system. Expressed principally in brain

### SNCA Blocking Peptide (C-term) - Protocols

Provided below are standard protocols that you may find useful for product applications.

• Blocking Peptides